Lizhu Pharmaceuticals (01513) is now up more than 4%. As of press release, it has risen 3.68% to HK$26.75, with a turnover of HK$37.1567 million.
According to the news, Livzon Pharmaceuticals announced that it plans to use its own funds or self-raised funds to repurchase some A-shares through centralized bidding transactions. The repurchase price per share shall not exceed RMB 45, and the total capital shall not be less than RMB 0.6 billion or less than RMB 1 billion. The repurchase of shares will completely cancel them and reduce the registered capital.
Pacific Securities pointed out that the injectable leuprorelin acetate microspheres passed the consistency evaluation and became the world's first long-term gonadotropin-releasing hormone release hormone approved for bioequivalence studies in accordance with the US FDA Drug Guidelines. The injectable triprorelin acetate microsphere endometriosis was approved for marketing. Production of injectable ariprazole microspheres was reported in 2023. Supplements have been successfully submitted and are expected to be approved for marketing in the first half of 2025. Furthermore, key biological products are progressing steadily.
